Pure Global

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function - Trial NCT05515458

Access comprehensive clinical trial information for NCT05515458 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chipscreen Biosciences, Ltd. and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05515458
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05515458
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
Study to Evaluate the Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Study Focus

Renal Impairment

Chiglitazar

Interventional

drug

Sponsor & Location

Chipscreen Biosciences, Ltd.

Timeline & Enrollment

Phase 1

Sep 30, 2022

Dec 30, 2023

24 participants

Primary Outcome

Cmax,AUC0-t and AUC0-inf

Summary

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic
 (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with
 renal impairment compared to subjects with normal renal function.

ICD-10 Classifications

Renal failure
Disorders resulting from impaired renal tubular function
Disorder resulting from impaired renal tubular function, unspecified
Other disorders resulting from impaired renal tubular function
Acute renal failure

Data Source

ClinicalTrials.gov

NCT05515458

Non-Device Trial